Antibodies that protect against many non-polio enteroviruses
Human Antibody Cross-Reactivity in Non-Polio Enteroviruses
Finding how some people's antibodies can fight many different non-polio enteroviruses to help design broader vaccines and treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11307584 on NIH RePORTER |
What this research studies
This project collects blood from adults to see which antibodies people naturally make against different non-polio enteroviruses. Researchers will stimulate memory B cells from those blood samples to create monoclonal antibodies and map the exact virus parts those antibodies bind. They will compare antibody patterns across hundreds of healthy adults to measure how common cross-reactive responses are. That knowledge will be used to guide design of vaccine components that preserve the B cell targets needed for broad protection.
Who could benefit from this research
Good fit: Ideal participants are adults willing to give blood samples, including people who have had prior enterovirus infections or exposures.
Not a fit: People with an active enterovirus infection who need immediate medical care, infants and very young children who cannot provide blood samples, or those seeking direct treatment are unlikely to receive direct benefit from participating.
Why it matters
Potential benefit: If successful, this work could lead to vaccines or antibody treatments that protect against many different enteroviruses and reduce cases of meningitis, acute flaccid myelitis, myocarditis, and neonatal sepsis.
How similar studies have performed: Poliovirus vaccines have long prevented severe disease, recent EV-A71 vaccines have been effective, and lab studies showed monoclonal antibodies can protect mice from AFM-like disease, so the approach builds on promising prior results.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Vogt, Matthew R — Univ of North Carolina Chapel Hill
- Study coordinator: Vogt, Matthew R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.